profit from every $100 of sales.
$0$100
Ensysce Biosciences
$0.36+0.03% today
-82.3% in 1 year
1-year low $0.251-year high $2.07
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Ensysce Biosciences sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$10.2 million of profit last year.
SalesProfit
Ensysce Biosciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Ensysce Biosciences | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Ensysce Biosciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -24 | -11 | -7 | -10 | |
| -24 | -10 | -7 | -10 | |
| -24 | -11 | -8 | -10 | |
| -2,091.60 | -70.40 | -11.45 | -3.98 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 6 | 3 | 6 | 7 |
| Cash | 3 | 1 | 4 | 4 |
| Total debt | 4 | 1 | 0 | 0 |
| Total liabilities | 10 | 3 | 2 | 5 |
| -4 | -0 | 4 | 3 | |
| 0 | 0 | 1 | 5 | |
| -2,645.5% | -1,525.9% | -131.9% | -227.9% | |
| 650.8% | 3,287.2% | -215.4% | -316.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -18 | -11 | -8 | -8 | |
| – | – | – | 0 | |
| -18 | -11 | -8 | -8 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 1 | 0 | 0 |
Valuation
- –
- –
- –
- 0.3×
- 1.4×
- –
- 854,338.1×
- -111,416,733.7%
- -145.2%
- 0.0%
Profitability
- -33.4%
- -202.1%
- -200.8%
- -92.5%
- -0.0%
- -1,173.0%
- -375.0%
- -136.5%
- -355.0%
- 204.8%
Growth
- +9.4%
- –
- −4.0%
- –
- +134.9%
Financial health
- 854,338.8×
- 95,437.06
- 4,115,516.5%
- -545.7×
- 1.59
- 1.59
- 0.68
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 33%of 958
Bottom 45%of 889
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -0.52 | -0.73 | +28.8% |
| Mar 30, 2026 | -0.75 | -1.26 | +40.5% |
| Nov 14, 2025 | -1.29 | -0.85 | −51.8% |
| Aug 13, 2025 | -0.79 | -1.02 | +22.5% |
| May 13, 2025 | -1.39 | -3.02 | +54.0% |
| Mar 10, 2025 | -2.90 | -2.74 | −5.8% |
| Nov 12, 2024 | 1.05 | -4.50 | +123.3% |
| Aug 14, 2024 | -3.30 | -5.85 | +43.6% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
28No pass
Benjamin Graham
57No pass
Philip Fisher
27No pass
Peter Lynch
23No pass
Joel Greenblatt
0No pass
Charlie Munger
24No pass
Terry Smith
26No pass
Questions about Ensysce Biosciences
Is Ensysce Biosciences a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Ensysce Biosciences AI analysis
What does Ensysce Biosciences do?
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It is in Biotechnology.
Does Ensysce Biosciences pay a dividend?
No. Ensysce Biosciences does not pay a dividend at the moment.
Is Ensysce Biosciences stock halal?
No. Ensysce Biosciences does not pass our halal screen: its cash and confirmed interest-bearing investments are 62% of its market value, at or above the 33% limit. How we check
How has Ensysce Biosciences stock done over the past year?
Down 82.3% over the past twelve months, to $0.36. It traded between $0.25 and $2.07 and is 82.6% below its high.
Who are Ensysce Biosciences's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Ensysce Biosciences's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.